<DOC>
	<DOCNO>NCT01466413</DOCNO>
	<brief_summary>This early phase study compare two fix dose study compound ELAPR Restylane® Vital Light ( control ) , multiple intradermal injection 3cm x 3cm area upper arm dermis . All subject receive three treatment , 3 week apart . Each treatment consist 16 injection total , 10mm apart grid formation 3cm x 3cm area mid - deep dermis medial aspect upper arm . Each injection consist 20-30ul product deliver use 30Gx¼ '' needle .</brief_summary>
	<brief_title>Two Formulations ELAPR Compared Restylane® Vital Light Following Repeat Implants Upper Arm Dermis</brief_title>
	<detailed_description>Each subject also receive Restylane® Vital Light ( control ) opposite arm follow treatment regimen use technique . A 4mm skin biopsy take implant site Cohort A subject ( include replacement ) Day 169 , Cohort B subject ( include replacement ) Day 85 . The biopsy encompass needle point tattoo centre implant site . The biopsy site close single stitch follow standard aftercare procedure stitch removal 7 10 day later .</detailed_description>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Age 35 50 year Male Female Good general health status Able give inform consent Clinically significant abnormality haematology biochemistry test Bleeding diathesis anticoagulant drug thrombocytopenia clinically significant prolonged APTT PT Chronic use aspirin , nonsteroidal antiinflammatory drug antiplatelet agent History keloid formation Systemic corticosteroid within last 12 week Diabetes metabolic disorder may interfere subject 's response treatment opinion investigator Any serious medical condition opinion investigator would strong possibility require systemic corticosteroid medication Pregnancy/lactation Previously receive Tropoelastin A history anaphylaxis allergic reaction include know hypersensitivity Hyaluronic acid lidocaine Sensitivity Restylane® Vital light Restylane product Use investigational product intend implant site previous 12 month . Sensitivity topical local anaesthetic cream ( EMLA® ) follow condition EMLA contraindicate : dermatitis , Methaemoglobinaemia , Glucose6phosphate dehydrogenase deficiency `` Mollusca Contagiosa ''</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Intrinsic Aging Skin</keyword>
</DOC>